OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-12-31-accounts

B•WEL RESEARCH bowel cancer and bowel dlsease Anhu?I Report and . Financial Statements For the year ended 31 December 2022 FR FUNDRAISING REGULATOR www.bowelresear¢huk.ory lundralslng@bowelresea￿huk.Ory ,020 3540 8694

Annual Repoitand Finaiicièl stalen￿t5 For Ilieyearended 31 December2022 Research is more than testing new drugs. It means better care. better treatments with medicines. better surgeryll better support. better quality of life and better chances of survlval.

B•WEL RESEARCH UK. Let's end bowel cancer and bowel dlsease Financial Review www.bowelresearchuk.ory

B•WEL RESEARCH UK. Let's end bowel cancer and bowel dlsease Financial Statements For the year ended 31 December 2022 www.bowelresearchuk.org


forthe year ended 31Decemb
er 2022
Restricted Unrestricted Total
funds funds funds
Note 2022
f		 2022f 2022f
Income from:
Donations and legacies 890,926 120,494 1,011,420
Charitable
Income		 9,132 9,132
Investments 25,960 25,960
Totallncome 926,018 120,494 1,046,512
Exlsendlture on:
Raising Funds (254,376) (254,376)
Charitable activities 5 (456,201) (456,201)
Total expenditure (710,577) (710,577)
Net income 215,441 120,494 335,935
Other recognised gains and losses
Other gains/losses (128,789) (128,789)
Net movement
Infunds		 86,652 120,494 207,146
Reconciliation offunds
Total Funds brought forward 348,470 235,326 583,796
Total funds carried forward 19 435,122 355,820 790,942

forthe year ended 3'i Decem ber 2021
Restricted Unrestricted Total
funds funds funds
Note 2021f 2021f 2021f
income from:
Donations
and legacies		 699,617 158,765 858,382
Charitable
Income		 85,540 85,540
Investments 29,198 29,198
Total income 814,355 158,765 873,120
Expenditure
on:
Raising Funds (217,413) (217,413)
Charitable
activities		 5 (895,552) (66,)69) (961,721)
Total expenditure (1,112,965) (66,168) (1,179,134)
Gains/(losses)
on investment		 assets 83,475 83,475
Net (expenditure)/income (2)5,135) 92,596 (i22,539)
Transfers between
funds		 40,600 (40,600)
Net movement
in funds		 86,652 120,494 207,146
Reconciliation offunds
Total Funds brought forward 348,470 235,326 583,796
Total funds carried forward 19 435,122 355,820 790,942


asat31Dec
emb
er 2021
Note 2022f 2021f
Fixed assets
Tangible assets 11 115 2,339
Investments 12 810,101 938,890
810,216 941,229
Current assets
Debtors 13 180,806 247,206
Cash at bank and in hand 1,269,266 1,286,651
2,286,033 1,533,857
Creditors: amounts falling due within one year 14 (1,204,613) (1,403,211)
Net current assets 245,459 130,646
Total assets less current liahilitles 1,055,675 1,071,875
Creditors: amounts falling due after more than one year 15 (264,733) (488,079)
Net assets excluding pension asset 790,942 583,796
Funds ofthe charity:
Restricted funds 355,820 235,326
Unrestricted
funds		 435,122 348,470
Total funds 19 790,942 583,796

forthe year ended
31December 2022
2022 2021
Note 5 E
Cash ttows from operatins activities
Net cash income/(expenditure) 207,146 (122,539)
Adjustments
to		 cash flows from non-cash items
Depreciation 2,224 1,879
Investment
income		 4 (25,960) (29,198)
Net losses/(gains) on investments 128,789 (83,475)
312,199 (233,333)
Working capital adjustments
Decrease/(increase) in debtors 13 66,400 (115,407)
(Decrease)/increase in creditors 14 (421,944) 147,460
Net cash flows from operating activites (43,345) (201,280)
Cash flows from Investing activities
Interest receivable 25,960 29,198
Net decrease
in cash and cash		 equivalents (17,385) (172,082)
Cash and cash equivalents
at 1		 January 1,286,65 1,458,733
Cash and cash equivalents
at 31 December		 1,269,266 1,286,651

2.Income from donations and legacie s
Restricted Unrestricted Total
funds funds funds
2022f 2022f 2022f
Donations 454,455 500 454,955
Legacies 428,201 428,201
Grants 8,270 119,994 128,264
890,926 120,494 1,011,420
Restricted Unrestricted Total
funds funds funds
2021
f.		 2021f 2021f
Donations 508,135 508,135
Legacies 81,345 81,345
Grants 110,137 158,765 268,902
699,617 158,765 858,382
3.Income from charitable activities
Unrestricted Total
funds funds
2022
f.		 2022f
Research 9,132 9,132
Unrestricted Total
funds funds
2021f 2021f
Research 85,540 85,540
4.Investment income
Restricted Unrestricted Total
funds funds funds
2022f 2022f 2022f
Dividends 25,846 25,846
Interest 114 114
25,960 25,960
Restricted Unrestricted Total
funds funds funds
2021f 2021f 2021
Dividends 29,198 29,198
29,198 29,198

charitab le activities
Summary by fund type Unrestricted Restricted Total
funds funds funds
2022f 2022f 2022f
Direct costs 25,515 25,515
Research 112,202 112,202
Grant funding ofactivities 206,825 206,825
Allocated support costs 111,659 111,659
456,201 456,201
Summary by fund type Unrestricted Restricted Total
funds funds funds
2021
f.		 2021f 2021f
Direct costs 21,299 21,299
Research 118,282 118,282
Grant funding ofactivities 567,485 66,169 633,654
Allocated support costs 188,486 188,486
895,552 66,169 961,721

Annual
Report and Ftnanaai Statements
For the year ended 31 December 2022
6.Grants Awarded
Total Total
2022f 2021f
Percutaneous
infracoccygeal
Botulinum
toxin injection for treatment
dyssynergic
defaecation		 of 4,103
Development
ofa blood test tofind early signs ofcolorectal cancer
people with inflammatory
bowel disease		 in 75,000
New strategies
for improving
radiotherapy
response
in bowel cancer		 74,919
Investigating
variations
in two genes that increase the risk ofbowel		 cancer 74,574
Utility ofMotility-MIR
in the assessment
ofFeorgut Neuromuscular
in children
with Paediatric
Intestinal
Pseudo-Obstruction		 Function 50,000
Identify new strategies to prevent
immune
cells supporting
liver metastasis
in colorectal cancer		 50,000
Treatment
pathway to improve bowel control after bowel resection
colorectal cancer		 for 50,000
Effectiveness ofan Acceptance and Commitment
Therapy based
psychological
intervention
on reducing
psychological
distress
in those
diag nored with Gastro-intestinal
Dysmotility		 49,994
Understanding
how immune
dysfunction
impacts ulverative
colitis
human
mini colons		 using 49,708
Causes ofrare and severe complications
ofPaediatric Inflammatory
Disease		 Bowel 49,013
Investigating
the role ofbacteria-infecting
viruses
in inflammatory
disease		 bowel 48,950
IBDSelf management 46,186
Decision-making
in complex pelvic exentreration
surgey for patients with
locally advanced
or recurrent
rectal cancer		 39,923
International
collaboration
to improve
management
ofpatients with rare
retrorectal
tumors		 18,007
Laparoscopy orAntibiotics
for Managing
Appendicitus		 16,205
Marshall Wave 15,000
Parastomal
hernia and shared decision making		 107,579
Identification
ofspatial biomarkers
in colorectal cancer		 84,246
Grants withdrawn (62,928)
206,825 633,654

2022 2021
No No
Employees 5 5
1he number ofemployees whose employee benefits (excluding employer pension costs) exceeded f60,00was:
2022 2021
No No
580,001 - E90,000 1

Director ofFundraising and Director of Re search .
2022f 2021
E
Wages and Salaries 155,376 301,969
Social security costs 11,471 33,094
Contribution todefined contrlbutlon pension schemes 5,853 13,836
172,700 348,899
During the year there were termination payments made which amounted tofNil (2021-E26 585).There was ENil
(2021 - ENil) outstanding atthe end ofthe year.
9.Auditors'
remuneration
2022 2021
E f.
Fees payable tothe auditor forthe audit ofthe annual costs 8,400 7,350
Preparation
ofthe financial statements		 2,040 1,825
10,440 9,175

The charity is a registered
charity and istherefore exe
applicable to charitable
purposes
only.
S.Tangible fixed assets		 mpt from taxation to the extent that it's income and gains are
Offlce
Equipmentf Totalf
Cost
At1 January 2022 6,671 6,671
At 31December 2022 6,671 6,671
Depreciation
At 1 January
2022		 4,332 4,332
Charge for the year 2,224 2,224
At 31 Deceber 2022 6,556 6,556
Net book value
At 31December 2022 115 115
At 31December 2021 2,339 2,339
12.Fixed asset investments
Listed
Investmentsf Totalf
Costorvaluation
At 1January 2022 938,890 938,890
(Losses) (128,789) (128,789)
At 31 December 2022 810,101 810,101
Net book value
At 31 December 2022 810,101 810,101
At 31 December 2021 938,890 938,890
13.Debtors
2022f 2021f
Trade debtors 2,946 13,226
Prepayments
and accrued income		 177,860 233,553
Other debtors 427
'IS0,606 247,206
12.Fixed asset investments
2022f 2021f
Trade creditors 115,302 143,906
PAVE/NIC 5,569
Grants payable 1,062,127 1,209,458
Accruals and deffered income 21,615 49,847
1,204,613 1,403,211
The balance ofdeffered income is recognised based on the following:
2022
f.		 2021f
Deffered income at 1January 2022 18,265 88,694
Amounts
released from previous periods		 (8,270) (70,429)
Deferred income atyear end 9,995 16,265
Deffered income relates to grant income received in advance ofthe work being performed.
12.Creditors: amounts falling due after one year
2022f 2021
Grants payable 264,733 488,079

16.Reconcili ation ofgrants payable
2022f 2021f
Grants commitment b/fwd 1January 2022 1,697,537 1,543,574
Commitments
made in the		 period 206,825 696,582
Grants paid during the period (577,502) (479,691)
Grant commitments withdrawn (62,928)
Grant commitments atyear end 1,326,860 1,697,537

Other
Balance at recosnlsed Balance at
1January Gains/ 31December
2022
5		 Incomef (Losses)
5		 2022
5
Unrestricted funds
General Funds 348,470 926,018 (710,577) (128,789) 435,122
Restricted funds
PhD fund-
Ulcerative
Colitis		 49,726 49,726
Role ofAdam 17
in the gut 3,813 3,813
Lucy Thomas Fund 20,560 20,560
Robin Charitable Trust 11,000 11,000
Nasbo Project Funding 1,880 1,880
David and Ruth Lewis
Charitable
Trust		 3,000 3,000
ELFStudy 7,000 7,000
Catherine Cookson 10,000 10,000
Sylvia and Colin
Shepherd
CT		 500 500
NSW Davidson 20,000 20,000
Kendrick and Sylvia
Edwards 500 500
Borelli 50,000 50,000
Twist 49,994 49,994
Steel Charitable Trust 10,000 10,000
ACPGBI 10,000 10,000
The Medical Research
Council 107,847 107,847
Total
Restricted funds 235,326 120,494 355,820
Totaloffunds 583,796 1,046,512 (710,577) (128,789) 790,942

Atdate
BRVK Other
became recognised Balance at
sole Transfers Galas/ 31December
member
5		 Income
E		 Expenditure f ln/out
E		 (Losses)
E		 2022
8
Unrestricted
funds
General Funds 523,005 814,355 (1,112,965) 40,600 83,475 348,470
Restricted funds
PhD fund 65,169 (65,169)
PhD fund-
Ulcerative
Colitis		 49,726 49,726
Role ofAdam 17
in the gut 3,813 3,813
Lucy Thomas Fund 11,742 8,818 20,560
Graham
Kirkham
Foundation 5,000 (5,000)
KMcDonald
General Charitable Trust 5,000 (5,000)
Robin Charitable Trust 11,000 11,000
Nasbo Project Funding 'I,880 1,880
David and Ruth Lewis
Charitable
Trust		 3,000 3,000
ELFStudy 7,000 7,000
David
Br Ruth Lewis		 26,600 (26,600)
Hospital Saturday Fund 2,000 (2,0001
G W Turner Trust 2,000 (2,000)
M Jackson 1,000 (1,000)
Catherine
Cookson		 10,000 10,000
Sylvia and Colin
Shepherd
CT		 500 500
NSW Davidson 20,000 20,000
The Medical Research
Council 107,847 107,847
Total
Restricted funds 183,330 158,765 (66,169) (40,600) 235,326
Totaloffunds 706,335 973,120 (1,179,134) 83,475 583,796

20.Analysis ofnet assets bet
Analysis ofnet assets between funds		 ween funds
Unrestricted Total funds at
funds Restricted 31December
Generalf fundsf 2022
Tangible fixed assets 115 115
Fixed asset investments 810,101 810,101
Current assets 1,094,252 355,820 1,450,072
Creditors due within one year (1,204,613) (1,204,613)
Creditors due in more than one year (264,733) (264,733)
Total 435,122 355,820 790,942
Total funds at
Unrestricted Restricted 31December
fundsf fundsf 2021f
Tangible fixed assets 2,339 2,339
Fixed asset investments 938,890 938,890
Current assets 1,298,531 235,326 1,533,857
Creditors due within one year (1,403,211) (1,403,211)
Creditors due in more than one year (488,079) (488,079)
Total 348,470 235,326 583,796

BIl)WEL RESEARCH UK. c/oThe Royal College ofsurgeons ofEngland 35-43 Lincoln's Inn Fields London WC2A 3PE www.bow•lresearchuk.org ReglsteredCharftyNo1l86C61, incorporated andregi%teredin En9land8ndWa￿,